Guideline Profile : Diabetes Mellitus
You are here : Home > Formulary Search > Guideline Profile : Diabetes Mellitus
Documentation
Drugs
Below are listed all drugs that are used to treat Diabetes Mellitus.
- Acarbose
- Alogliptin
- Alogliptin/metformin
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Canagliflozin
- Canagliflozin/metformin
- Dapagliflozin
- Dapagliflozin/metformin
- Dulaglutide
- Empagliflozin
- Empagliflozin/metformin
- Ertugliflozin
- Glibenclamide
- Gliclazide
- Glimepiride
- Glipizide
- Glyxambi (Linagliptin/empagliflozin)
- Insulin Aspart - Fiasp
- Insulin aspart - NovoRapid
- Insulin Aspart - Trurapi
- Insulin degludec
- Insulin degludec with liraglutide
- Insulin detemir
- Insulin glargine - Abasaglar
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Insulin Glargine - Toujeo
- Insulin glulisine - Apidra
- Insulin Lispro - Humalog
- Insulin Lispro - Lyumjev
- Insulin pump - non-autoimmune causes
- Insulin pump - Type 1 diabetes
- Isophane (neutral insulin) - hypurin porcine 30/70
- Isophane Insulin - Humulin I
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Linagliptin
- Linagliptin/metformin
- Liraglutide
- Metformin hydrochloride
- Metformin hydrochloride/pioglitazone
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Pioglitazone hydrochloride
- Repaglinide
- Saxagliptin
- Saxagliptin/dapagliflozin
- Semaglutide
- Sitagliptin
- Soluble insulin - Hypurin porcine neutral
- Soluble insulin - Actrapid
- Soluble insulin - Humulin S
- Sotagliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Tirzepatide
- Tolbutamide
- Vildagliptin
Committee Recommendations (4)
Following the February 2026 updates to NICE NG28: Type 2 Diabetes in Adults, the Surrey Heartlands APC agreed to adopt the following resources to support clinicans in managing the use of medicines in type 2 diabetics:
There are SPS resources to support healthcare professionals (HCP) in taking actions to promote the safer use of insulin. It aims to equip HCPs with insights, support, and shared learning, to address practice with insulin that may lead to harm. See link below.
GLP-1 receptor agonists can impact female hormones, including HRT and contraceptives, and reproductive health through various mechanisms. For further information and advice see links below.